Clinical trials: Renal Pelvis Cancer
Renal Vascular Disease, Nutcracker Syndrome, Renal
Renal Autotransplantation; Case Series
Renal autotransplantation (RAT) is a method of removing a kidney from its place of origin in a patient, repairing it, and transplanting it in another location of the body, generally the iliac fossa of the same patient.RAT is a…
- Conditions
- Renal Vascular Disease, Nutcracker Syndrome, Renal, Pelvic Trauma, Loin Pain-Hematuria Syndrome
- Trial name
- NCT05115812
- Testing
- Pre-Operative Information, Intra-Operative Data, Post-Operative Data (up to discharge)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Methodist Health System
Magnetic Resonance Imaging
Gadobutrol Magnevist-controlled Body Study
The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions.
- Trial name
- NCT01050829
- Testing
- Gadobutrol (Gadovist, BAY86-4875), Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
- Where
- 15 sites in China, Japan and 1 more
- Volunteers
- 370 people
- Sponsor
- Bayer
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Renal Cell Carcinoma, Adrenal Tumor
The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery
A single-arm clinical trial was designed in this study. The surgeon will perform urological telesurgery for patients using Chinese domestically produced "MicroHand S" surgical robot system.
- Conditions
- Renal Cell Carcinoma, Adrenal Tumor, Nonfunctioning Kidney, Renal Pelvis Carcinoma
- Trial name
- NCT05739812
- Testing
- telesurgery by domestic surgical robot
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Solid Cancers, Solid Tumor Cancer
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or…
- Conditions
- Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Trial name
- NCT06630247
- Testing
- XL495, ADC cytotoxic agents
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Exelixis
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Urothelial Carcinoma
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an effective and safe treatment for people who have urothelial carcinoma of the upper urinary tract.
- Trial name
- NCT05868265
- Testing
- Enfortumab Vedotin, Radical surgery
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic…
- Trial name
- NCT00004203
- Testing
- oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00005644
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 16 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Hematuria, Urothelial Carcinoma
Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria
Background Urothelial carcinoma (UC) is the most common malignancy of the urinary system. Hematuria is a significant clinical manifestation of UC, often diagnosed through invasive procedures.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06469229
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Changhai Hospital
Urinary Bladder Neoplasms, Neoplasm Metastasis
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Trial name
- FORAGER-1 (NCT05614739)
- Testing
- Vepugratinib, Pembrolizumab, enfortumab vedotin
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 677 people
- Sponsor
- Eli Lilly and Company
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one…
- Trial name
- NCT04865939
- Testing
- sterile water irrigation, Gemcitabine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- University of Texas Southwestern Medical Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006111
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 11 sites in France
- Volunteers
- 53 people
- Sponsor
- UNICANCER
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
- Trial name
- NCT02459119
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Ureter Cancer, Renal Pelvic Carcinoma
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
This is a prospective cohort study to analyse the safety and efficacy of postoperative adjuvant radiotherapy combined with immunotherapy versus surgery alone group of UTUC patients with T3-4 stages or lymph nodes metastasis(N+)…
- Conditions
- Ureter Cancer, Renal Pelvic Carcinoma, Advanced Urothelial Carcinoma
- Trial name
- NCT06598761
- Testing
- Immunotherapy+radiotherapy, surveillance alone
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter
Named Patient Program for Mitomycin for Pyelocalyceal Solution
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named…
- Conditions
- Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- NCT05494411
- Testing
- Mitomycin for pyelocalyceal solution
- Sponsor
- UroGen Pharma Ltd.
Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy.
- Conditions
- Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra, Urothelial Carcinoma Recurrent
- Trial name
- GRAPE (NCT06983210)
- Testing
- Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- Where
- Japan
- Volunteers
- 43 people
- Sponsor
- Nagoya University